​But the challenges are still there in terms of regulatory, so which is why if you have to play, banks are a better bet. So, I will play it through HDFC Bank rather than playing it individually through HDFC AMC or HDFC Life. So, if I have to ride that opportunity, banks are offering a slightly better option compared to chasing individual names.

The share touched a 52-week high of Rs 1,185.20 on November 1, 2022 and a 52-week low of Rs 852 and March 22, 2023

Nifty is close to reaching its all-time high due to foreign institutional investors' strong inflows; however, at least seven Nifty50 constituents must rally over 20% to reclaim their previous 52-week highs, including Adani Enterprises and Adani Ports. Gautam Adani's flagship firm, Adani Enterprises, must surge 65% to touch its 52-week high of Rs 4,190. Similarly, Infosys, Cipla, and Hindalco are among the stocks that must rise between 21-27% to reclaim their all-time high levels. On the other hand, Bajaj Finserv is languishing 28% away from its 52-week high level of Rs 1,844.

There are still a lot of moving parts. So I think from a domestic economy standpoint, we are well placed. However, from a global standpoint there are still, as you rightly said, there are a lot of moving parts.

The NSE Nifty index was trading 117.65 points up at 18617.0

The NSE Nifty index was trading 88.85 points up at 18588.2

Although Indian stock market valuations have dropped to their 5-year and 10-year historical averages, analysts still lack comfort in recommending investors to put money aggressively. However, nearly 50% of index stocks are below their 10-year averages, which can offer decent returns. UPL has the highest upside at 35% despite brokerage Prabhudas Lilladher slashing its FY24E/25E estimates by 16%/12% and target multiple from 14x earlier to 12x. Meanwhile, HDFC Bank, SBI, Axis Bank, and M&M have upwards of 20% upside potential each in the next 12 months.

"Cipla historically has always been a big respiratory and acute player but not that big in the diabetes area," said Umang Vohra, managing director and global CEO of Cipla in an interview to ET.

Sharekhan recommended Hold rating on Cipla with a target price of Rs 1030 in its research report dated May 23, 2023.

‘The Great Indian Consumption Story’ gave a fillip to banking, auto, telecom and FMCG firms, while the IT sector was the biggest casualty of the US banking crisis.

We examine the key fundamentals of the fund, its portfolio and performance to help you make an informed investment decision.

Glenmark Pharmaceuticals' Q4 consolidated profit before exceptional items and tax was INR3.09bn ($37.78m) for the quarter ended 31 March, down 12.3% compared to a year earlier, due to increased input costs and lower demand in the Indian drugs market. The firm posted one-time costs of INR8bn due to settlements over lawsuits in the US related to antitrust issues and consumer protection. While its sales rose 11.5%, the Indian drugs segment reported a 6.4% sales decline, accounting for 31% of its total, while North American sales grew by 15.3%.

KR Choksey is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1167 in its research report dated May 17, 2023.

The NSE Nifty index was trading 63.45 points down at 18223.05

The NSE Nifty index was trading 30.85 points down at 18368.0

HDFC, HDFC Bank, Maruti Suzuki, Power Grid and UPL were among the top losers on NSE.

The NSE Nifty index closed 84.05 points up at 18398.85

Adani Ent., Cipla, BPCL, Grasim Inds. and Divis Labs were among the top losers on NSE in today's trade.

The NSE Nifty index closed 84.05 points up at 18398.85

Neuland Labs, Shreyans Ind, Zensar Tech, Sukhjit Starch and Precision Camshaft, hit their fresh 52-week highs during the day.

Motilal Oswal recommended Neutral rating on Cipla with a target price of Rs 970 in its research report dated May 13, 2023.

Prabhudas Lilladher is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1070 in its research report dated May 14, 2023.

The NSE Nifty index was trading 56.45 points up at 18371.25

Cipla Q4: Motilal Oswal expect 12.3% earnings CAGR over FY23-25, led by 9%/11% sales CAGR in DF/NA segments and marginal improvement in profitability.

Adani Enterprises and Adani Transmission today announced that they would raise funds totalling Rs 21,000 crore through the qualified institutional placement (QIP) route.

According to Rahul Shah, VP-Equity Advisory, MOFSL, there could be a stock specific market from here onwards which is what is happening in spite of the straight 11 days and the FIIs buying.

The Board has also recommended the payment of a final dividend of Rs 8.50 per equity share for the financial year ended March 2023.

Shares of Adani Transmission and Adani Total Gas plummeted by 5% on Friday after they were removed from the MSCI Global Standard Index, effective May 2023. The removal is expected to trigger outflows of $201m for Adani Transmission and $186m for Adani Total Gas, according to a report by Nuvama Alternative & Quantitative Research.

Tata Motors is expected to report a net profit of between INR 3,100 to 3,204 crore and revenue growth of up to 34% for Q4 on the back of strong EBITDA expansion across divisions. DLF will post a small increase with reported net profits at INR 477 crore, whereas Vedanta may experience a 48% decline with net profits anywhere between INR 2,168 crore to 2,618 crore. Cipla is expected to report a 5% YoY growth for domestic sales, but Kotak suggests a 16% decline in South Africa for the March quarter.

FPIs continue to remain net buyers, investing Rs 837.21 crore on Thursday. DIIs sold shares worth Rs 200 crore.

Deepak Nitrite's net profit fell 12% to Rs 234 crore for the quarter ended March. Meanwhile, the revenue from operations stood at Rs 1,961 crore in the same period.

Cipla Q4 preview: The company is expected to double its consolidated net profit to Rs 723.4 crore from Rs 362.07 crore in the year-ago quarter. It is also seen as the biggest beneficiary of a strong flu season in India

Dr. Reddys, L&T, Hindalco, Bharti Airtel and Cipla were among the top losers on NSE.

At Tuesday's closing price, Mankind Pharma was valued at a price-to-earnings ratio of 43 times its FY22 earnings. Mankind is now India's fifth largest pharma company by market value of ₹57,046 crore. Sun Pharma, Divi's Lab, Dr. Reddy's Lab, and Cipla are currently valued between ₹75,284 crore and ₹2.31 lakh crore.

As a part of the association IRM India Affiliate and Jio will organise webinars, roundtables, industry meetings, and thought leadership articles towards knowledge building to enhance ERM and risk intelligence for the sector.

Bajaj Auto's standalone net profit fell 2% to Rs 1,433 crore for the fourth quarter ended March. It was Rs 1,469 crore in the same period last year.

"Among the sectors which are still to report earnings numbers, auto is an important one because on an incremental basis, it is driving the net profits of coverage and that is also in the Nifty 50 Index quite significantly. Then, one will have to wait and see how some of the other larger companies report, especially on the consumer side and consumption demand is not looking that great at this point in time."

At least 8 of the 50 stocks in India's Nifty50 index are dangerously close to their 52-week low levels, according to analysis. Infosys, the Indian IT company, is the closest to its 1-year low, just 4% away from its Rs 1,185 ($15.76) mark. A total of four IT stocks feature in the list, which analysts said were among the worst affected sectors, affected by domestic and global headwinds.

Sun Pharma, Dr. Reddys, Cipla, Divis Labs and UPL were among the top losers on NSE.

Sandip Sabharwal is optimistic about the growth prospects of large banks in India, particularly ICICI Bank. He also highlights the railway investment theme as strong and suggests identifying stocks that can benefit disproportionately. In terms of IT, while there is a definite slowdown that could persist over the following year, there are specific companies with specific projects or businesses that will stand out.